IL-13Rα2 Inibidores

Os inibidores comuns da IL-13Rα2 incluem, entre outros, BAY 11-7082 CAS 19542-67-7, Teofilina CAS 58-55-9, Prednisona CAS 53-03-2, Wortmannin CAS 19545-26-7 e Everolimus CAS 159351-69-6.

IL-13Rα2 inhibitors comprise a diverse range of compounds that can indirectly modulate the activity of IL-13Rα2 by targeting various signaling pathways associated with immune response and inflammation. These inhibitors work through different mechanisms, influencing IL-13Rα2 activity by altering the upstream or downstream signaling elements of the pathways in which IL-13Rα2 is involved IL-13Rα2 inhibitors comprise a diverse range of compounds that can indirectly modulate the activity of IL-13Rα2 by targeting various signaling pathways associated with immune response and inflammation. These inhibitors work through different mechanisms, influencing IL-13Rα2 activity by altering the upstream or downstream signaling elements of the pathways in which IL-13Rα2 is involved.

Compounds such as JAK inhibitors, STAT6 inhibitors, and NF-κB inhibitors exemplify this class by reducing IL-13Rα2 activity through their roles in cytokine signaling and inflammatory pathways. Similarly, phosphodiesterase inhibitors and glucocorticoids can indirectly inhibit IL-13Rα2 through their effects on immune cell signaling and inflammation, impacting IL-13Rα2's role in these processes. Other notable compounds in this class include PI3K inhibitors, mTOR inhibitors, and MAPK inhibitors, each influencing different aspects of cellular regulation and signaling. By modulating pathways like PI3K/AKT, mTOR, and MAPK signaling, these inhibitors can indirectly affect IL-13Rα2's function in immune signaling. Additionally, compounds like IKK inhibitors, HDAC inhibitors, and proteasome inhibitors demonstrate the ability to inhibit IL-13Rα2 through their influence on NF-κB activity, gene expression, and protein turnover.